Lipid profile and others atherogenic risk factors in low lead level exposure mice;Perfil lipídico y otros factores de riesgo aterogénicos en ratones expuestos a bajas concentraciones de plomo

Acta Bioquimica Clinica Latinoamericana

Volumn 37, Issue 4, 2003, Pages 395-400

  Sant Yacumo, Roque Alberto ^a   Martínez Riera, Nora ^a,b   Riera De Martínez Villa, Nora ^a,c  

^a UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

^b Epidemiología

^c Universidad Nacional de Tucuman UNT Facultad de Medicina   (Argentina)

Author keywords

Atherosclerosis risk; Lead; Lipid profile

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEAD; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PORPHOBILINOGEN SYNTHASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; LEAD POISONING; MOUSE; NONHUMAN; PLASMA VISCOSITY; PROTEIN BLOOD LEVEL; RISK FACTOR;

ANIMALIA;

EID: 1642460847     PISSN: 03252957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Riera De Martínez Villa N, Bibas Bonet H, Martínez Riera N, Valdéz C. Plomo: Efectos Biológicos, Experimentales y Clínicos (Parte I) Rev Fac Med Tuc 1987; 19 (2): 8-12.
2. Riera de Martínez Villa N, Bibas Bonet H, Martínez Riera N, Valdéz C. Plomo: Efectos Biológicos, Experimentales y Clínicos (Parte II) Rev Fac Med Tuc 1990; 21 (1): 17-21.
3. Martínez Riera N, Sant Yacumo R, Riera de Martínez Villa N. Efectos de la exposición a bajas concentraciones de plomo en ratones sobre diferentes parámetros bioquímicos. Rev Toxicol 2001; 18: 82-6.
4. Rozhada DA, Dermaku S, Halili F, Berisha A, Rizvanolli S. Total blood serum lipids and cholesterol of laboratory rats exposed to industrial pollutants. Acta Biol Med Exp 1980; 4 (2): 93-6.
5. Vodichenska TS S, Dinoeva SK. Content of lead in water sources and its effect on the development of experimental atheroesclerosis. GIG SANIT 1980; 0 (11): 69-72.
6. Basavaraju SR, Jones TD. Atheroesclerosis risk from chemicals: Part I. Toxicological observations and mechanisms of atheroesclerosis. Arch Environm Contam Toxicol 1998; 35 (1): 152-64.
7. Kristal-Boneh E, Coller D, Froom P, Harari G, Ribata J. The association between ocupational lead exposure and serum cholesterol and lipoprotein levels. Am J Public Health 1999; 89 (7): 1083-7.
8. Schroeder HA, Balassa JJ. Influence of Chromium, Cadmium, and Lead on Rat Aortic Lipids and Circulating Cholesterol. Am J Physiol 1965; 209 (2): 433-7.
9. Burch HB, Siegel AL. Improved method for measurement of delta-aminolevulinic acid dehydratase activity in human erythrocytes. Clin Chem 1971; 17: 1038-41.
10. Wiener Lab. Vademecum 1996: Manuales de instrucciones y sistemas analíticos. Wiener Lab. Rosario, Argentina.
11. International Committee for Standarization in Haematology. Recommendation for Selected Method for the Measurement of Plasma Viscosity. J Clin Pathol 1984; 37: 1147-52.
12. Destaing F, Duzer A, Ferrand B, Potier A. Dosage du fibrinogène par la micro-methode de coagulation de von Clauss. Pathol Biol 1960; 8, 17/18: 1615-21.
13. http://www.nap.edu/catalog-16k Guide for the Care and use of Laboratory animals. Institute of laboratory animal resources. Comission on life Sciences. National Research Council National Academy. Press Washington DC; 1996.
14. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997; 96: 4204-10.
15. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzki LH, et al. Guide to primary prevention of cardiovascular diseases: A Statement for Healthcare Professionals From Prevention From de Task Force on Risk Reduct. Circulation 1997; 95: 2329-31.
16. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
17. Ross R, Fuster V. The pathogenesis of atherosclerosis. En: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven; 1996. p. 441-60.
18. Ross R. Mechanisms of Disease; Atherosclerosis-An Inflammatory Disease. N Engl J Med 1999; 340: 115-26.
19. Martín Dolz C, Hernández Ribas R, Rojo Rodes JE. Factores de riesgo no convencionales. Clín Invest Ateroes 2000; 5 (12): 285-96.
20. Prerovska HA, Drdkova S. The effect of chronic exposure to industrial toxins and the development of atheroesclerosis in exposed workers. Casopis Lekaru Ceskych 1967; 106: 754-9.
21. Benini F, Calamussi V. Porphyrin metabolism and blood cholesterol in workers exposed to tetraethyl and tetramethyl lead and to inorganic lead. Arcisp st Anna Ferrara 1970; 23 (6): 640-7.
22. Antonowicz J, Andrzejak R, Lepetow L, Skocynska A, Smolik R. Blood lipid parameters in smelters chronically exposed to heavy metals. Med Pr 1996; 47 (3): 207-15.
23. Skoczinska A, Smolik R, Milian A. The efect of Combined exposure to lead and cadmium on serum lipids and lipid peroxides levels in rats. Inter J Occup Med Environnent health 1994; 3 (7): 263-71.
24. Skoczinska A, Smolik R, Jelen M. Lipid abnormalities in rats given small doses of lead. Arch Toxicol 1993; 67 (3): 200-4.
25. Gatanova TM. Charasterictics of the serum lipids in workers of lead industry. Med Tr Prom Ekol 1994; 12: 17-21.
26. Jialal I, Devaraj S. Inflammation and atherosclerosis: the value of hight-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001; 116 Suppl: S108-15.
27. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65: 168-72.
28. Kuller LH, Tracy RP, Shaten J, Meilahn EN. For the MRFIT Research Group. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996; 144: 537-47.
29. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
30. Stein O, Dabach Y, Hollander G, Ben-Nain M, Halperin G, Stein Y. Effect of atherogenic diet on reverse cholesterol transport in vivo in atheroesclerosis susceptible (C57BL/6) and resistant (C3H) mice. Atheroesclerosis 2001; 156 (2): 307-13.
31. Shi W, Wang NJ, Shih DM, Sun VZ, Wang X, Lusis AJ. Determinants of atheroesclerosis susceptibility in the C3H and C57BL/6 mouse model: evidence for involvement of endothelial cells but not blood cells or cholesterol metabolism. Circ Res 2000; 86 (10): 1078-84.
32. Matrai A, Schunbein H, Ernest E. Red Cell Agregation Low Shear Blood Viscosity and Erythrocyte Sedimentation Rate Correlate with Surface Rheology of Plasma. Clin Hemorheol 1985; 5: 629-34.
33. Pirofsky B. Hematocrite in function of absolute viscosity in normal blood. J Clin Invest 1953; 32: 292-7.
34. Stoltz SF, Donner M. Erythrocyte agregation experimental approaches and clinical implications. Int Angiol 1987; 6: 193-202.
35. Carr ME, Powers PL. Differential effects of divalent cations on fibrin structure. Blood Coagul Fibrinol 1991; 2 (6): 741-7.
36. Fatah K, Hessel B. Effect of Zinc ions on fibrin network structure. Blood Coagul Fibrinol 1998; 9 (7): 629-35.
37. Lipinski B, Lipinska I. Effect of magnesium on fibrin formation from lower molecular weight fibrinogen. Magnes Res 2000; 13 (4): 233-7.
38. Goldmann BU, Hamm CW. Risk stratification in acute coronary syndrome. Herz 2001; 1: 24-9.